Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bmab 1200 versus Stelara in moderate to severe chronic plaque psoriasis
2021-006668-25Phase 3Completed
- Sponsor
- Mylan
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Bmab 1200 with Stelara (2 arms). Primary endpoint: Percentage change from baseline in Psoriasis Area and Severity Index score at Week 12. Started May 2022; status: completed.
02
Drugs
Starjemzaustekinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2021-006668-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006668-25.